Cagrilintide: Peptide Profile, CAS & Properties
CAS 1415456-99-3 · 4409 g/mol
Cagrilintide (CAS 1415456-99-3) is a 37-amino-acid acylated long-acting amylin analogue and AMY/CTR receptor agonist with molecular formula C194H312N54O59S2 (~4409 g/mol). It is investigational, in clinical development for obesity and weight management, and not yet approved by major regulators. This page provides reference information on Cagrilintide.
- CAS Number
- 1415456-99-3
- Molecular Formula
- C194H312N54O59S2
- Molecular Weight
- 4409 g/mol
- Drug Class
- long-acting amylin analogue
What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue — a 37-amino-acid acylated peptide that acts as an agonist at amylin (AMY) and calcitonin (CTR) receptors. It is built on a pramlintide-like amylin backbone with sequence substitutions and N-terminal acylation by a C20 eicosanedioic fatty di-acid attached through a γGlu linker, plus an intramolecular disulfide bridge. The acylation drives albumin binding and confers a long elimination half-life, supporting once-weekly subcutaneous administration in clinical studies.
As an active pharmaceutical ingredient (API), cagrilintide (CAS 1415456-99-3, molecular formula C194H312N54O59S2, ~4409 g/mol) is typically handled as a lyophilised powder for formulation work. It is being studied for obesity and weight management, including as part of a fixed combination with a GLP-1 receptor agonist. Cagrilintide is investigational: it is in clinical development and has not been approved by the FDA, EMA or other major regulators.
How Cagrilintide Is Produced & Characterised
Cagrilintide is a synthetically demanding acylated peptide: the 37-mer length, the disulfide bridge requiring controlled oxidative folding, and the lipid side-chain conjugation all create opportunities for deletion sequences, diastereomers, mis-folded variants and incomplete acylation. As reference background for this peptide class, production is generally based on Fmoc solid-phase peptide synthesis (SPPS) with controlled disulfide formation and side-chain conjugation, followed by purification on preparative dynamic axial compression (DAC) HPLC columns that isolates the target sequence from closely related impurities, and lyophilisation to a stable powder.
Quality control for acylated amylin analogues of this type typically combines UPLC/HPLC for purity, LC-MS for confirmation of sequence and disulfide connectivity, and characterisation of water content, counter-ion (acetate) content and residual solvents. These analytical approaches reflect general industry practice for complex therapeutic peptides and are described here as educational reference information only.
Typical Specifications & Properties
Pharmaceutical-grade cagrilintide is commonly described as a white to off-white lyophilised powder. Reference purity for research- and clinical-grade material is typically reported at ≥99.0% by UPLC/HPLC, with individual impurities controlled below about 0.10% and verified by LC-MS impurity profiling. Stability is generally evaluated under ICH Q1A(R2) long-term and accelerated conditions, with storage usually recommended at low temperature, protected from light and moisture.
Key physicochemical reference data include the molecular formula C194H312N54O59S2, an approximate molecular weight of 4409 g/mol, and a 37-residue sequence acylated with a C20 di-acid side chain and stabilised by one intramolecular disulfide bridge. These values are provided as a general molecular reference and are not a product specification.
Regulatory & Development Context
Cagrilintide is an investigational molecule: it is in clinical development for obesity and weight management and has not been approved by the FDA, EMA or other major regulators. It has been studied both as a standalone once-weekly amylin analogue and in fixed combination with a GLP-1 receptor agonist.
For investigational peptides such as cagrilintide, chemistry, manufacturing and controls (CMC) information is generally organised under CTD Module 3 to support IND/CTA submissions, with analytical methods validated to ICH Q2(R1) and stability assessed to ICH Q1A(R2). This section summarises the general regulatory framework that applies to molecules of this type and reflects cagrilintide's current investigational status; it is reference information and not therapeutic guidance.
Cagrilintide API — Specifications
| CAS Number | 1415456-99-3 |
|---|---|
| Molecular Formula | C194H312N54O59S2 |
| Molecular Weight | 4409 g/mol |
| Sequence | 37 amino acids, acylated (C20 di-acid), one disulfide bridge |
| Drug Class | Long-acting amylin analogue (AMY/CTR agonist) |
| Regulatory Status | Investigational — in clinical development, not yet approved |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + DAC prep-HPLC purification |
| Form | Lyophilised powder |
| Storage | Store at -20°C, protected from light & moisture |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Investigational; in clinical development and not yet approved by the FDA, EMA or other major regulators. Used only in pharmaceutical R&D and as a reference standard.
Cagrilintide API — Frequently Asked Questions
What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue — a 37-amino-acid acylated peptide that acts as an agonist at amylin (AMY) and calcitonin (CTR) receptors. It is built on a pramlintide-like backbone with a C20 fatty di-acid acylation and an intramolecular disulfide bridge, and is being investigated for obesity and weight management.
What is the CAS number and molecular weight of Cagrilintide?
Cagrilintide's CAS number is 1415456-99-3, its molecular formula is C194H312N54O59S2, and its molecular weight is approximately 4409 g/mol. It is a 37-amino-acid peptide acylated with a C20 fatty di-acid side chain and containing one intramolecular disulfide bridge.
Is Cagrilintide approved by the FDA or EMA?
No. Cagrilintide is investigational — it is in clinical development for obesity and weight management and has not been approved by the FDA, EMA or other major regulators.
What class of peptide is Cagrilintide?
It is a long-acting amylin analogue. Pharmacologically it acts as a dual agonist at amylin (AMY) and calcitonin (CTR) receptors, and its fatty-acid acylation promotes albumin binding for an extended half-life suited to once-weekly subcutaneous dosing in studies.
What is Cagrilintide being studied for?
Cagrilintide is being studied for obesity and weight management, both as a standalone once-weekly amylin analogue and as part of a fixed combination with a GLP-1 receptor agonist. It remains investigational and has not been approved for therapeutic use.
How is Cagrilintide produced and characterised?
As general reference background, peptides of this class are produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled disulfide-bridge formation and lipid side-chain conjugation, followed by preparative HPLC purification and lyophilisation. Characterisation typically uses UPLC/HPLC for purity and LC-MS to confirm sequence and disulfide connectivity.
Related Peptide APIs
Eloralintide API
CAS 2883634-40-8
GLP-1 & Incretin Multi-AgonistsSemaglutide API
CAS 910463-68-2
GLP-1 & Incretin Multi-AgonistsAmycretin API
CAS 3005889-81-3
GLP-1 & Incretin Multi-AgonistsRetatrutide API
CAS 2381089-83-2
Technical Reference Page
WinHyCare neither supplies nor manufactures Cagrilintide; this page is provided as a technical reference. The peptide API we supply is Semaglutide.